Short Interest Worth Mentioning: Time to Reconsider COCRYSTAL PHARMA INCORPORATED (OTCBB:COCP) After Less Short Sellers?

November 30, 2016 - By Ellis Scott   ·   0 Comments

Short Interest Worth Mentioning: Time to Reconsider COCRYSTAL PHARMA INCORPORATED (OTCBB:COCP) After Less Short Sellers?

The stock of COCRYSTAL PHARMA INCORPORATED (OTCBB:COCP) registered a decrease of 1.67% in short interest. COCP’s total short interest was 2.32 million shares in November as published by FINRA. Its down 1.67% from 2.36 million shares, reported previously. With 245,100 shares average volume, it will take short sellers 10 days to cover their COCP’s short positions. The stock decreased 3.04% or $0.014 on November 29, hitting $0.446. About 96,466 shares traded hands. Cocrystal Pharma Inc (OTCBB:COCP) has declined 35.71% since April 27, 2016 and is downtrending. It has underperformed by 40.94% the S&P500.

Cocrystal Pharma, Inc., formerly Biozone Pharmaceuticals, Inc., is engaged in developing medicines for use in the treatment of human viral diseases. The company has a market cap of $333.69 million. The Firm develops technologies and approaches to create antiviral drug candidates. It currently has negative earnings. The Firm is developing antiviral therapeutics that inhibit the replication function of a virus, including the ribonucleic acid -dependent RNA polymerase enzyme, the helicase enzyme and the NS5A protein of hepatitis C virus (HCV), and the polymerase enzymes of influenza virus and norovirus.

COCP Company Profile

Cocrystal Pharma, Inc., formerly Biozone Pharmaceuticals, Inc., incorporated on November 21, 2014, is engaged in developing medicines for use in the treatment of human viral diseases. The Firm develops technologies and approaches to create antiviral drug candidates. The Firm is developing antiviral therapeutics that inhibit the replication function of a virus, including the ribonucleic acid (RNA)-dependent RNA polymerase enzyme, the helicase enzyme and the NS5A protein of hepatitis C virus (HCV), and the polymerase enzymes of influenza virus and norovirus. The polymerase inhibitors include both nucleosides (Nucs) and non-nucleosides. The Company’s platform consists of computation, medicinal chemistry, click chemistry and X-ray crystallography. The Firm determines the structures of cocrystals containing the inhibitors bound to the enzyme or protein to guide its design. The Firm uses computational methods to screen and design product candidates using its cocrystal structural information.

More notable recent Cocrystal Pharma Inc (OTCBB:COCP) news were published by: Bizjournals.com which released: “RFS Pharma merges with Cocrystal Pharma” on November 25, 2014, also Money.Cnn.com with their article: “Cocrystal Pharma Announces In-Licensing of CRISPR Cas Technologies for …” published on February 10, 2016, Seekingalpha.com published: “Cocrystal Pharma: Small Cap Company With Transformative Merger (COCP)” on November 27, 2014. More interesting news about Cocrystal Pharma Inc (OTCBB:COCP) were released by: Seekingalpha.com and their article: “Cocrystal Pharma – Overhyped Biotech Or The Next Pharmasset? (COCP)” published on April 07, 2015 as well as Medgadget.com‘s news article titled: “Cocrystal Pharma, Inc. Clinical Trial Reviews and Clinical Trail Assessment …” with publication date: November 22, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Ellis Scott


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>